

References

I-198

1. Clinical Pharmacology™ 2020 Tampa FL: Gold Standard, Inc. Burosumab.
2. Crysvida (burosumab-twza), injection, for subcutaneous use [package insert]. Ultragenyx Pharmaceutical, Inc. Novato, Ca. Revised 06/2020.
3. Ruppe M. X-Linked Hypophosphatemia. GeneReviews. 2017.
4. Hayes, Inc. Hayes Health Prognosis Overview. Crysvida (Burosumab-twza; formerly KRN23). Lansdale, PA: Hayes, Inc.; April; 2018.
5. Micromedex DrugDex Compendium®. 2020. Burosumab (Crysvida)
6. Insogna K, Rauch F, Kamenicky P, et. al. Burosumab improved histomorphometric measures of Osteomalacia in adults with X-linked hypophosphatemia: A phase 3, single –arm, international trial. *Journal of Bone and Mineral Research*. 2019;34 (12): 2183-2191.
7. Day, A. L., Gutiérrez, O. M., Guthrie, B. L., et. al. Burosumab in tumor-induced osteomalacia: A case report. *Joint bone spine*. 2020. 87(1):81-83